The Variable Association Between Expression and Methylation of Estrogen Receptors and the Survival of Patients with Different Tumors

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2020 Jun 15

PMID 32536040

Citations 7

Authors

Chao Hu

Yinhua Liu

Shan Jiang

Hongjin Chen

Haojun Xu

Junhong Hu

Congzhu Li

Hongping Xia

Affiliations

Soon will be listed here.

Abstract

Background: Estrogen receptor (ER) is essential in reproductive development and is also the primary driver of breast cancers. Deregulation of ER may also be involved in tumorigenesis of other organs. To understand the role of ER in different tumor types, pan-cancer analysis of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) in various tumors and association with patients' survival were conducted using The Cancer Genome Atlas (TCGA) data.

Results: Gene methylation level was evaluated by the mean methylation level of CpG sites in the promoter region. The significant different DNA methylation between tumor and healthy tissues was shown in 10 tumor types for ESR1 and eight tumor types for ESR2. The methylation pattern was also varied across different TCGA tumors. The pan-cancer analysis showed significantly different mRNA expression of ESR1 in nine tumor types and ESR2 in four tumor types. Survival analysis showed that the effects of ERs expression on survival are diverse in different tumors. The expression of ERs was associated with tumor molecular subtypes and various clinical characteristics. ER correlated genes were mainly enriched in cancer and immune-related pathways.

Conclusions: Our pan-cancer analysis data indicated that ERs might be significantly associated with carcinogenesis and progression of some tumors, which may be potential therapeutic targets and prognosis biomarkers.

Citing Articles

Methylation of promoter induced by SNAI2-DNMT3B complex promotes epithelial-mesenchymal transition and correlates with poor prognosis in ERα-positive breast cancers.

Li J, Deng Q, Zhu J, Min W, Hu X, Yu Chen H MedComm (2020). 2023; 4(6):e403.

PMID: 37881785 PMC: 10594044. DOI: 10.1002/mco2.403.

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function.

Belluti S, Imbriano C, Casarini L Cancers (Basel). 2023; 15(18).

PMID: 37760622 PMC: 10526871. DOI: 10.3390/cancers15184653.

DNA methylome and transcriptome profiling reveal key electrophysiology and immune dysregulation in hypertrophic cardiomyopathy.

Li X, Fan H, Song X, Song B, Liu W, Dong R Epigenetics. 2023; 18(1):2195307.

PMID: 37005704 PMC: 10072074. DOI: 10.1080/15592294.2023.2195307.

DNA hypomethylation mediates immune response in pan-cancer.

Zhang C, Sheng Q, Zhao N, Huang S, Zhao Y Epigenetics. 2023; 18(1):2192894.

PMID: 36945884 PMC: 10038033. DOI: 10.1080/15592294.2023.2192894.

Epigenetic Regulation of Estrogen Receptor Genes' Expressions in Adipose Tissue in the Course of Obesity.

Kozniewski K, Wasowski M, Jonas M, Lisik W, Jonas M, Binda A Int J Mol Sci. 2022; 23(11).

PMID: 35682668 PMC: 9181405. DOI: 10.3390/ijms23115989.

References

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Sunakawa Y, Cao S, Berger M, Matsusaka S, Yang D, Zhang W . Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. Pharmacogenomics J. 2015; 17(1):36-41. PMC: 7496219. DOI: 10.1038/tpj.2015.77. View

Bondesson M, Hao R, Lin C, Williams C, Gustafsson J . Estrogen receptor signaling during vertebrate development. Biochim Biophys Acta. 2014; 1849(2):142-51. PMC: 4269570. DOI: 10.1016/j.bbagrm.2014.06.005. View

Chaturantabut S, Shwartz A, Evason K, Cox A, LaBella K, Schepers A . Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes. Gastroenterology. 2019; 156(6):1788-1804.e13. PMC: 6532055. DOI: 10.1053/j.gastro.2019.01.010. View

Yi J, Kim S, Kim J, Seong C, Yu H, Chai Y . Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol. 2017; 24(12):3754-3762. DOI: 10.1245/s10434-017-5780-z. View

He J, Zhao H, Deng D, Wang Y, Zhang X, Zhao H . Screening of significant biomarkers related with prognosis of liver cancer by lncRNA-associated ceRNAs analysis. J Cell Physiol. 2019; 235(3):2464-2477. DOI: 10.1002/jcp.29151. View

. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017; 169(7):1327-1341.e23. PMC: 5680778. DOI: 10.1016/j.cell.2017.05.046. View

Kirn V, Zaharieva I, Heublein S, Thangarajah F, Friese K, Mayr D . ESR1 promoter methylation in squamous cell cervical cancer. Anticancer Res. 2014; 34(2):723-7. View

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts R, Pearson A, Tarazona N . Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7(313):313ra182. PMC: 4998737. DOI: 10.1126/scitranslmed.aac7551. View

10.

Williams C, DiLeo A, Niv Y, Gustafsson J . Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett. 2015; 372(1):48-56. PMC: 4744541. DOI: 10.1016/j.canlet.2015.12.009. View

11.

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

12.

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti R, Limonta P . Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne). 2016; 7:140. PMC: 5080294. DOI: 10.3389/fendo.2016.00140. View

13.

. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163(4):1011-25. PMC: 4695400. DOI: 10.1016/j.cell.2015.10.025. View

14.

Anbalagan M, Rowan B . Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol Cell Endocrinol. 2015; 418 Pt 3:264-72. DOI: 10.1016/j.mce.2015.01.016. View

15.

Mathur R, Zhang Y, Grimmer M, Hong C, Zhang M, Bollam S . MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020; 22(11):1580-1590. PMC: 8444710. DOI: 10.1093/neuonc/noaa059. View

16.

Natale C, Li J, Zhang J, Dahal A, Dentchev T, Stanger B . Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife. 2018; 7. PMC: 5770157. DOI: 10.7554/eLife.31770. View

17.

Sood S, Patel F, Ghosh S, Arora A, Dhaliwal L, Srinivasan R . Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation. Clin Oncol (R Coll Radiol). 2015; 27(12):720-7. DOI: 10.1016/j.clon.2015.08.001. View

18.

Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M . Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007; 39(5):655-60. DOI: 10.1038/ng2006. View

19.

Wu E, Wong L, Hernandez B, Ji J, Jia W, Kwee S . Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2019; 4. PMC: 6347119. DOI: 10.20517/2394-5079.2018.87. View

20.

Prossnitz E, Barton M . The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011; 7(12):715-26. PMC: 3474542. DOI: 10.1038/nrendo.2011.122. View